A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) and A.D.A.M. Innovations announced a strategic partnership on October 16, 2025 to bring AI-powered liquid biopsy genomic testing and a companion diagnostic (CDx) to Japan.

The collaboration will launch the MSK-ACCESS® liquid biopsy application powered by SOPHiA DDM™, analyze samples in-house at A.D.A.M.'s Tokyo lab, and pursue development of a local CDx to support personalized oncology, faster turnaround times, lower patient costs, and pharmaceutical trial support. A.D.A.M. has completed over 2.8 million genomic tests and has operated in Japan for over 20 years.

Insights

Commercialization and Regulatory Strategist

Partnership to localize SOPHiA DDM™ and MSK-ACCESS® in Japan should expand access to liquid biopsy and enable CDx development.

By combining A.D.A.M. Innovations local high-throughput laboratory and regulatory expertise with the AI-powered SOPHiA DDM™ platform, the agreement creates a clear operational path to offer the MSK-ACCESS® liquid biopsy test in-country. Local sample analysis and the matched tumor-normal approach cited should materially shorten turnaround times and lower per-patient costs while maintaining accuracy by reducing false positives; those mechanics support wider clinical uptake and use in trials.

Dependencies and risks hinge on successful regulatory clearance for a companion diagnostic in Japan and on operational scale-up within the Tokyo lab. The announcement explicitly assigns regulatory submission support to A.D.A.M. Innovations, but approval timelines and requirements remain decisive and will determine whether the test becomes an authorized CDx.

Concrete near-term milestones to watch: regulatory submission progress and any formal CDx approvals in 2025–2026, local launch timing and measured reductions in turnaround time, and partnerships with pharmaceutical sponsors for CDx use in clinical programs. Monitor reported metrics such as number of local tests performed and any regulatory decisions over the next 6–18 months for evidence of impact.

ROLLE, Switzerland and TOKYO, Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company pioneering data-driven medicine, today announced at ESMO a strategic agreement to bring cutting-edge liquid biopsy genomic testing to the Japanese population. The companies will also partner to commercialize a liquid biopsy companion diagnostic aimed at advancing personalized and precision cancer care in Japan.

As a market leader for genetic testing in Japan with a high-throughput laboratory located in central Tokyo, A.D.A.M. Innovations has served the Japanese population for over 20 years and completed over 2.8 million genomic tests to-date. A.D.A.M. Innovations will continue its legacy of bringing global innovations to Japan by adopting the AI-powered SOPHiA DDM™ Platform to advance personalized cancer testing across the country.

The partnership will initially focus on launching the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDM^TM. This innovative liquid biopsy test is designed to detect actionable genomic alterations from a single blood draw, leveraging state-of-the-art AI to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner. The test utilizes a matched tumor-normal approach which improves accuracy and avoids false positives. By launching the test locally and analyzing samples in-house, A.D.A.M. Innovations will expedite testing turnaround times, reduce costs to patients, and advance local cancer research.

As part of the partnership, the companies also aim to develop a liquid biopsy companion diagnostic (CDx) test in Japan. By developing the application into a CDx, more patients can gain access to the benefits of the high-quality tumor profiling test, advancing personalized healthcare at scale. The offering will also provide pharmaceutical partners with a powerful new tool to accelerate drug development and market access in Japan. The companies will collaborate across all steps of the development process, with A.D.A.M. Innovations leveraging its deep clinical and regulatory expertise to support regulatory submissions in Japan.

"Making precision oncology more accessible to patients in Japan is a significant milestone," said Ross Muken, President, SOPHiA GENETICS. "By combining A.D.A.M. Innovations' strong clinical expertise and local presence with the global reach of the SOPHiA DDM™ Platform, we can drive the nationwide adoption of data-driven medicine, advancing both clinical research and the delivery of personalized oncology care."

"For over two decades, we have supported academic, research and medical institutions with advanced clinical genomic testing," commented Michel Mommejat, President of A.D.A.M. Innovations. "Through our partnership with SOPHiA GENETICS and its AI-driven platform, we are taking a major step forward in accelerating precision oncology across Japan. Testing locally enables faster turnaround times, reduces costs, enhances patient care, and supports global CDx deployments."

The collaboration was formally announced from the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin. The announcement underscores both companies' shared commitment to advancing data-driven and liquid biopsy-based solutions for cancer care in Japan. Learn more by connecting with SOPHiA GENETICS and A.D.A.M. Innovations at ESMO booth #2039 from October 17-21, 2025.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn. 

For more information on A.D.A.M. Innovations, visit ADAM-INNOVATIONS.COM or connect on LinkedIn. 

About SOPHiA GENETICS  
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements: 
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

About A.D.A.M. Innovations Co.
Founded in 2004 in Tokyo, A.D.A.M. Innovations (currently operating as Genesis Healthcare Co.) is a pioneer in genomics, AI, and precision health solutions. The company develops cutting-edge technologies spanning clinical diagnostics, consumer genetics, and AI-driven R&D data platforms. To date, it has conducted more than 2.8 million genetic tests and maintains the largest R&D genomic database of the Japanese population. The company's name will change to A.D.A.M. Innovations Co. effective November 1, 2025. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/adam-innovations-and-sophia-genetics-partner-to-advance-liquid-biopsy-testing-and-companion-diagnostics-for-precision-oncology-in-japan-302585695.html

SOURCE SOPHiA GENETICS

FAQ

What did SOPH and A.D.A.M. announce on October 16, 2025 regarding liquid biopsy in Japan?

They announced a strategic partnership to launch the MSK-ACCESS® liquid biopsy powered by SOPHiA DDM™ and to develop a liquid biopsy companion diagnostic in Japan.

How will the SOPH and A.D.A.M. partnership affect test turnaround times for Japanese patients?

A.D.A.M. will analyze samples in-house at its Tokyo lab, which the companies say will expedite turnaround times compared with overseas processing.

What is the scale of A.D.A.M. Innovations' testing experience cited in the announcement?

A.D.A.M. has operated in Japan for over 20 years and completed more than 2.8 million genomic tests to date.

Will the MSK-ACCESS® test launched by SOPH and A.D.A.M. require tissue samples or a blood draw?

MSK-ACCESS® is described as a liquid biopsy designed to detect actionable genomic alterations from a single blood draw using circulating tumor DNA.

How could the SOPH and A.D.A.M. collaboration support pharmaceutical partners in Japan?

The companies say the offering will serve as a tool to accelerate drug development and market access by enabling high-quality tumor profiling and potential CDx deployments.